(Reuters) -Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the ...

Novartis has made a takeover approach for rare disease-focused biotech Avidity Biosciences, as Big Pharma continues to hunt ...

Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical ...

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech ...

We recently published 10 Stocks With Easy 15-30% Upside. Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing ...

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

Swiss pharmaceutical giant Novartis is exploring a potential acquisition of U.S. biotech firm Avidity Biosciences, according ...

Novartis AG is weighing a takeover of rare disease-focused biotech firm Avidity Biosciences Inc. in a bid to boost its drug ...

This summary covers recent developments in health, including Novo Nordisk filing lawsuits against semaglutide compounders, ...

Glencore maintains its UK listing; Britain seeks clarity on China's embassy plans; Novartis considers acquiring biotech firm ...

Avidity Biosciences (RNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 7. Analyst Joseph Schwartz from Leerink Partners reiterated a Buy ...